TG Therapeutics Analyst Ratings
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $55
Strong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG Therapeutics
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $38
B.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $10
BofA Securities Adjusts Price Target on TG Therapeutics to $10 From $9, Maintains Underperform Rating
Jefferies Sticks to Their Buy Rating for TG Therapeutics (TGTX)
TG Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $43
J.P. Morgan Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $43
A Quick Look at Today's Ratings for TG Therapeutics(TGTX.US), With a Forecast Between $38 to $55
B. Riley Remains a Buyer of TG Therapeutics on Weakness Following Q3 Results
TG Therapeutics: Promising Growth Trajectory and Blockbuster Potential Justify Buy Rating
TD Cowen Initiates TG Therapeutics(TGTX.US) With Buy Rating, Announces Target Price $50
TG Therapeutics Initiated at Buy by TD Cowen
TG Therapeutics Price Target Announced at $50.00/Share by TD Cowen
TG Therapeutics Analyst Ratings
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $38
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $49